Caribou Biosciences, Inc. Contracts & Agreements

Offer Letter, dated (Filed With SEC on November 6, 2024)

Officer Employment Agreement by and between the Registrant and (Filed With SEC on November 6, 2024)

Amendment to the Officer Employment Agreement, dated July 27, 2021, by and between the Registrant and Steven B. Kanner, Ph.D (Filed With SEC on August 6, 2024)

Compensation Letter, dated (Filed With SEC on March 11, 2024)

Compensation Letter, dated February 20, 2024, from the Registrant to (Filed With SEC on March 11, 2024)

Separation Letter, dated December 19, 2023, between the Registrant and Syed Rizvi, M.D (Filed With SEC on March 11, 2024)

Offer Letter, dated (Filed With SEC on March 11, 2024)

Officer Employment Agreement by and between the Registrant and (Filed With SEC on March 11, 2024)

Underwriting Agreement, dated July 13, 2023, by and among the Company, BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C (Filed With SEC on July 17, 2023)

First Amendment to the Collaboration and License Agreement, dated February 21, 2023, between the Registrant and AbbVie Manufacturing Management Unlimited Company (Filed With SEC on March 9, 2023)

Side Letter to the Collaboration and License Agreement, dated January (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 16, 2023, from the Registrant to Rachel E. Haurwitz, Ph.D (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 16, 2023, from the Registrant to Jason V. OByrne (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 16, 2023, from the Registrant to Barbara G. McClung, J.D (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 16, 2023, from the Registrant to Steven B. Kanner, Ph.D (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 11, 2022, from the Registrant to Ruhi Khan (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 16, 2023, from the Registrant to Ruhi Khan (Filed With SEC on March 9, 2023)

Compensation Letter, dated February 16, 2023, from the Registrant to Syed Rizvi, M.D (Filed With SEC on March 9, 2023)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan of the Registrant (Filed With SEC on November 8, 2022)

Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2021 Equity Incentive Plan of the Registrant (Filed With SEC on November 8, 2022)

Description of Common Stock (Filed With SEC on March 21, 2022)

First Amendment, dated as of January 11, 2022, to Amended and Restated Office/Laboratory Lease by and between Registrant and 2929 Seventh St., LLC (Filed With SEC on March 21, 2022)

Rider 1 to Office/Laboratory Lease between the Registrant and 7th Street Property III General Partnership, effective as of the lease commencement date of January 13, 2022 (Filed With SEC on March 21, 2022)

Compensation Letter, dated February 11, 2022, from the Registrant to Rachel E. Haurwitz, Ph.D (Filed With SEC on March 21, 2022)

Offer Letter between the Registrant and Jason V. O'Byrne dated January 5, 2021 (Filed With SEC on March 21, 2022)

Compensation Letter, dated February 11, 2022, from the Registrant to Jason V. OByrne (Filed With SEC on March 21, 2022)

Compensation Letter, dated February 11, 2022, from the Registrant to Barbara G. McClung, J.D (Filed With SEC on March 21, 2022)

Compensation Letter, dated February 11, 2022, from the Registrant to Steven B. Kanner, Ph.D (Filed With SEC on March 21, 2022)

Officer Employment Agreement by and between the Registrant and Ruhi Khan, effective as of November 8, 2021 (Filed With SEC on March 21, 2022)

Compensation Letter, dated February 11, 2022, from the Registrant to Ruhi Khan (Filed With SEC on March 21, 2022)

Offer Letter, dated October 29, 2021, between the Registrant and Syed Rizvi (Filed With SEC on March 21, 2022)

Officer Employment Agreement by and between the Registrant and Syed Rizvi, effective as of January 18, 2022 (Filed With SEC on March 21, 2022)

Amendment to 2013 Equity Incentive Plan (effective December 9, 2021) (Filed With SEC on March 21, 2022)

Form of Employee Stock Option Agreement under the 2021 Equity Incentive Plan of the Registrant (Filed With SEC on March 21, 2022)

Form of Non-Employee Director Stock Option Agreement under the 2021 Equity Incentive Plan of the Registrant (Filed With SEC on March 21, 2022)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan of the Registrant (Filed With SEC on March 21, 2022)

Form of Stock Option Agreement under the 2013 Equity Incentive Plan, as amended and restated on April 3, 2019 (Filed With SEC on November 9, 2021)

Officer Employment Agreement, dated July 27, 2021, by and between the Registrant and Rachel E. Haurwitz, Ph.D (Filed With SEC on July 28, 2021)

Officer Employment Agreement, dated July 27, 2021, by and between the Registrant and Steven B. Kanner, Ph.D (Filed With SEC on July 28, 2021)

Officer Employment Agreement, dated July 27, 2021, by and between the Registrant and Barbara G. McClung, J.D (Filed With SEC on July 28, 2021)

Officer Employment Agreement, dated July 27, 2021, by and between the Registrant and Jason V. OByrne, M.B.A (Filed With SEC on July 28, 2021)

Form of Underwriting Agreement (Filed With SEC on July 19, 2021)

Leaseback Agreement, dated June 16, 2021, by and between the Registrant and Intellia Therapeutics, Inc (Filed With SEC on July 19, 2021)

Form of Officer Employment Agreement by and between the Registrant and Rachel E. Haurwitz, Ph.D. to be effective upon the closing of this offering (Filed With SEC on July 19, 2021)

Form of Officer Employment Agreement by and between the Registrant and Steven B. Kanner, Ph.D., to be effective upon the closing of this offering (Filed With SEC on July 19, 2021)

Form of Officer Employment Agreement by and between the Registrant and Barbara G. McClung, J.D., to be effective upon the closing of this offering (Filed With SEC on July 19, 2021)

Form of Officer Employment Agreement by and between the Registrant and Jason V. OByrne, M.B.A., to be effective upon the closing of this offering (Filed With SEC on July 19, 2021)

2021 Equity Incentive Plan of the Registrant (Filed With SEC on July 19, 2021)

2021 Employee Stock Purchase Plan (Filed With SEC on July 19, 2021)

2013 Equity Incentive Plan of the Registrant, as amended and restated April 3, 2019 (as amended March 1, 2021) (Filed With SEC on July 19, 2021)

Second Amended and Restated Investors Rights Agreement, dated March 2, 2021, by and among the Registrant and the investors listed therein (Filed With SEC on July 1, 2021)

Collaboration and License Agreement dated as of February 9, 2021, between the Registrant and AbbVie Manufacturing Management Unlimited Company (Filed With SEC on July 1, 2021)

Exclusive License Agreement dated as of November 13, 2020, by and between the Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on July 1, 2021)

Sale and Assignment Agreement, dated as of January 31, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Filed With SEC on July 1, 2021)

Amendment No. 1 to Sale and Assignment Agreement dated as of October 20, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Filed With SEC on July 1, 2021)

Amendment No. 2 to Sale and Assignment Agreement dated as of December 15, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Filed With SEC on July 1, 2021)

Amendment No. 3 to Sale and Assignment Agreement dated May 5, 2020, by and between the Registrant and ProMab Biotechnologies, Inc (Filed With SEC on July 1, 2021)

Amended and Restated Collaboration and License Agreement, dated as of July 13, 2015, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 1 to Amended and Restated Collaboration and License Agreement, dated as of January 21, 2016, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 2 to Amended and Restated Collaboration and License Agreement, dated as of July 18, 2016, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 3 to Amended and Restated Collaboration and License Agreement, dated as of March 13, 2017, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 4 to Amended and Restated Collaboration and License Agreement, dated as of June 26, 2017, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 5 to Amended and Restated Collaboration and License Agreement, dated as of May 25, 2018, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 6 to Amended and Restated Collaboration and License Agreement, dated as of June 2, 2019, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 7 to Amended and Restated Collaboration and License Agreement, dated as of December 18, 2020, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

Amendment No. 8 to Amended and Restated Collaboration and License Agreement, dated as of December 18, 2020, by and between the Registrant and Pioneer Hi-Bred International, Inc (Filed With SEC on July 1, 2021)

License Agreement dated as of July 16, 2014, by and between the Registrant and Intellia, LLC (Filed With SEC on July 1, 2021)

Amendment No. 1 to the License Agreement, dated February 2, 2016, by and between the Registrant and Intellia Therapeutics, Inc. as successor in interest to Intellia, LLC (Filed With SEC on July 1, 2021)

Addendum to License Agreement, dated as of February 2, 2016, by and between the Registrant and Intellia Therapeutics, Inc. as successor in interest to Intellia, LLC (Filed With SEC on July 1, 2021)

Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing, dated December 15, 2016, by... (Filed With SEC on July 1, 2021)

Exclusive License Agreement dated as of April 16, 2013, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)

Amendment No. 1 to the Exclusive License Agreement, dated April 16, 2013, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)

Amendment No. 2 to the Exclusive License Agreement, dated April 17, 2013, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)

Amendment No. 3 to the Exclusive License Agreement, dated April 16, 2021, by and among the Registrant, The Regents of the University of California, and the University of Vienna (Filed With SEC on July 1, 2021)

Memorandum of Understanding, dated March 14, 2019, by and among the Registrant, the University of Vienna, and the Regents of the University of California (Filed With SEC on July 1, 2021)

Amended and Restated Office/Laboratory Lease, dated March 31, 2021, by and between the Registrant and 2929 Seventh St., LLC (Filed With SEC on July 1, 2021)

Officer Employment Agreement, dated as of June 30, 2017, by and between the Registrant and Rachel E. Haurwitz, Ph.D (Filed With SEC on July 1, 2021)

Amendment No. 1 to Officer Employment Agreement, dated April 10, 2019, by and between the Registrant and Rachel E. Haurwitz, Ph.D (Filed With SEC on July 1, 2021)

Salary Increase Letter, dated February 19, 2021, from the Registrant to Rachel E. Haurwitz, Ph.D (Filed With SEC on July 1, 2021)

Officer Employment Agreement, dated as of June 30, 2017, by and between the Registrant and Steven B. Kanner, Ph.D (Filed With SEC on July 1, 2021)

Amendment No. 1 to Officer Employment Agreement, dated as of April 10, 2019, by and between the Registrant and Steven B. Kanner, Ph.D (Filed With SEC on July 1, 2021)

Salary Increase Letter, dated June 14, 2019, from the Registrant to Steven B. Kanner, Ph.D (Filed With SEC on July 1, 2021)

Officer Employment Agreement, dated as of June 30, 2017, between the Registrant and Barbara G. McClung, J.D (Filed With SEC on July 1, 2021)

Amendment No. 1 to Officer Employment Agreement, dated as of April 10, 2019, by and between the Registrant and Barbara G. McClung, J.D (Filed With SEC on July 1, 2021)

Salary Increase Letter dated as of June 14, 2019, from the Registrant to Barbara G. McClung, J.D (Filed With SEC on July 1, 2021)

Officer Employment Agreement, dated as of February 8, 2021, between the Registrant and Jason V. OByrne, M.B.A (Filed With SEC on July 1, 2021)

2013 Equity Incentive Plan of the Registrant, as amended and restated April 3, 2019 (Filed With SEC on July 1, 2021)

Form of Stock Option Agreement under the 2013 Equity Incentive Plan, as amended and restated (Filed With SEC on July 1, 2021)

2012 Stock Option/Stock Issuance Plan of the Registrant (Filed With SEC on July 1, 2021)

Form of Stock Option Agreement under the 2012 Stock Option/Stock Issuance Plan (Filed With SEC on July 1, 2021)

Promissory Note, dated November 27, 2018 made by Rachel E. Haurwitz, Ph.D. in favor of the Registrant (Filed With SEC on July 1, 2021)

Pledge and Security Agreement, dated November 27, 2018, by and between the Registrant and Rachel E. Haurwitz, Ph.D (Filed With SEC on July 1, 2021)

Form of Indemnification Agreement between the Registrant and its directors and officers (Filed With SEC on July 1, 2021)

Scientific Advisory Board Agreement, dated as of June 18, 2012, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Amendment No. 1 to Scientific Advisory Board Agreement, dated as of April 12, 2014, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Amendment No. 2 to Scientific Advisory Board Agreement, dated as of May 31, 2016, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Amendment No. 3 to Scientific Advisory Board Agreement, dated as of January 1, 2017, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Amendment No. 4 to Scientific Advisory Board Agreement, dated as of March 31, 2018, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Amendment No. 5 to Scientific Advisory Board Agreement, dated as of January 1, 2020, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Scientific Advisory Board Agreement, dated January 1, 2017, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Mutual Termination of the Scientific Advisory Board Agreement, dated March 17, 2018, by and between the Registrant and Jennifer A. Doudna (Filed With SEC on July 1, 2021)

Series C Preferred Stock Purchase Agreement, dated March 2, 2021, by and among the Registrant and the parties listed therein (Filed With SEC on July 1, 2021)

Third Amended and Restated Voting Agreement, dated March 2, 2021, by and among the Registrant and the parties listed therein (Filed With SEC on July 1, 2021)

First Amendment to Third Amended and Restated Voting Agreement, dated March 29, 2021, by and among the Registrant and the parties listed therein (Filed With SEC on July 1, 2021)

Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated March 2, 2021, by and among the Registrant and the parties listed therein (Filed With SEC on July 1, 2021)

Public Offering Participation Rights Agreement, dated March 2, 2021, by and between the Registrant and PFM Health Sciences, LP (Filed With SEC on July 1, 2021)

Public Offering Participation Rights Agreement, dated March 2, 2021, by and between the Registrant and Ridgeback Capital Investments LP (Filed With SEC on July 1, 2021)

Public Offering Participation Rights Agreement, dated March 2, 2021, by and between the Registrant and Zone III Healthcare Holdings, LLC (Filed With SEC on July 1, 2021)

Category

Industry

Companies

Contracts

Caribou Biosciences, Inc. Contracts & Agreements